

SAIS NEWSLETTER AUGUST 23rd, 2019

Dear SAIS members,

Below, please find this week's newsletter.

FUNDING CALLS, CONFERENCES, WEBINARS and ANNOUNCEMENTS

"Imaging Africa" Microscopy and Image Analysis Workshop for African Researchers - 13-17 January 2020 - Cape Town, SA

<https://www.imagingafrica.org/>. Places are limited and applications for the workshop close on the 15th October 2019.

Combining Procalcitonin and a Highly Multiplexed Syndromic Respiratory Panel to Optimize Antimicrobial Stewardship in Patients with Lower Respiratory Tract Infections - Labroots webinar - August 29 - 10:00 AM PDT

Learning Objectives: * Understand how to reduce antibiotic exposure with highly predictive low procalcitonin levels and positive highly multiplexed syndromic respiratory panel results; * Understand the high incidence of unnecessary antibiotics in viral infections. To register -<https://www.labroots.com/webinar/combining-procalcitonin-highly-multiplexed-syndromic-respiratory-panel-optimize-antimicrobial-stewar>.

Upcoming deadlines for the January 2020 Keystone Symposia meetings

*** Tuberculosis: Immunity and Immune Evasion - January 16-20**

Discounted abstract deadline: September 24, Discounted registration deadline: November 19. <https://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1689>.

*** Tissue Immunity - January 26-29**

Discounted abstract deadline: September 26, Discounted registration deadline: November 21. <https://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1725>.

The Labroots 5th Annual Microbiology and Immunology Virtual Event - September 11-12 from 6:00 AM PDT

During the free, two-day event, participants will explore and discover new concepts, tools and techniques to apply to ongoing research and diagnostics. Please visit <https://www.labroots.com/ms/virtual-event/microbiology-immunology-2019> to register.

eLife Special Issue on Cancer Immunology - call for papers

Highlighting recent advances in the mechanistic understanding of the immune response to cancer cells and new discoveries that relate to therapeutic interventions, the Special Issue continues to accept submissions until September 30, 2019. <https://elifesciences.org/inside-elifesciences/2110c5c4/special-issue-two-months-to-submit-your-cancer-immunology-paper>.

British Society for Immunology Congress 2019 - 2-5 December - Liverpool, UK (open for international researchers)

This is the UK's premier immunology event attracting over 1,000 delegates to enjoy an extensive 4-day programme of cutting-edge research from leading UK and international researchers. Abstract submission deadline: 9 September 2019. <https://www.immunology.org/events/british-society-for-immunology-congress-2019>.

15 Biotech-themed online courses (may be of interest to researchers)

<https://labiotech.eu/tops/online-course-biotech-coursera-edx/>.

PUBLICATIONS and INTERESTING READS:

In situ vaccination: a cancer treatment a century in the making

Injecting immunostimulants directly into the tumor is not a new strategy to stimulate the immune system, but the approach has seen a surge of interest in recent years. <https://www.the-scientist.com/news-opinion/in-situ-vaccination--a-cancer-treatment-a-century-in-the-making-66201>.

Laboratory mice born to wild mice have natural microbiota and model human immune responses

<https://science.sciencemag.org/content/365/6452/eaaw4361>.

Trial in Africa probes antibiotic's effects on child mortality

In Niger, fewer kids die when health workers administer azithromycin routinely, perhaps because of a shift in the composition of gut microbes. <https://www.the-scientist.com/news-opinion/trial-in-africa-probes-antibiotics-effects-on-child-mortality-66270>.

FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs

Approval marks the second drug approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs and signals FDA's continued focus on facilitating development of new treatments to fight antimicrobial resistant infections. <https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs>.

The FDA-approved oral drug Nitazoxanide amplifies host antiviral responses and inhibits Ebola virus (open access)

[https://www.cell.com/iscience/fulltext/S2589-0042\(19\)30228-7](https://www.cell.com/iscience/fulltext/S2589-0042(19)30228-7).

Immune cell bank bets on future CAR T success (interesting read)

The company Cell Vault offers to hold consumers' T cells for later use, but scientists suggest the service would benefit very few users. <https://www.the-scientist.com/news-opinion/immune-cell-bank-bets-on-future-car-t-success-66290>.

Circulating CXCR5-PD-1hi peripheral T helper cells are associated with progression to type 1 diabetes (open access)

<https://link.springer.com/article/10.1007%2Fs00125-019-4936-8>.

The immune landscape of cancer (open access)

[https://www.cell.com/immunity/fulltext/S1074-7613\(19\)30330-9](https://www.cell.com/immunity/fulltext/S1074-7613(19)30330-9).

Class-switch recombination occurs infrequently in germinal centers (open access)

[https://www.cell.com/immunity/fulltext/S1074-7613\(19\)30317-6](https://www.cell.com/immunity/fulltext/S1074-7613(19)30317-6).

Lighting up proteins with Immuno-SABER

A simple and robust DNA-based signal amplification method to simultaneously visualize multiple proteins in tissues has the potential to accelerate many large-scale protein mapping and biomarker discovery projects. <https://wyss.harvard.edu/lighting-up-proteins-with-immuno-saber/>.



Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (open access)

[https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018\(19\)30196-1/fulltext](https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(19)30196-1/fulltext).

Enteropathogen antibody dynamics and force of infection among children in low-resource settings (open access)

<https://elifesciences.org/articles/45594>.

USP49 potently stabilizes APOBEC3G protein by removing ubiquitin and inhibits HIV-1 replication (open access)

<https://elifesciences.org/articles/48318>.

Mucosal infection rewires TNF α signaling dynamics to skew susceptibility to recurrence (open access)

<https://elifesciences.org/articles/46677>.

JOBS

SAHIVCS is hiring a Project Manager

SAHIVCS is looking for skilled project manager to work within PEPFAR/USAID-funded projects. Please find details below.



LOOKING FOR A SKILLED
PROJECT MANAGER TO WORK
WITHIN PEPFAR/USAID
FUNDED PROJECTS.

JOIN OUR
TEAM!

Requirements:

- Post-graduate degree in public health and/or other relevant discipline
- Management qualification or equivalent experience required
- Must have clinical knowledge and understanding especially in the HIV/AIDS field
- 5 – 7 years' experience as a project manager
Experience running PEPFAR programmes is essential





CV and covering letter to rebecca@sahivcs.org

**SAHIVCS is hiring a Marketing Intern**

SAHIVCS is looking for an energetic, self-motivated marketing intern, who is interested to learn many aspects of marketing and branding in a healthcare/HIV/NGO context. Please email renata@sahivcs.org. For more details, please see below.

SOUTHERN AFRICAN HIV
CLINICIANS SOCIETY

BE OUR MARKETING INTERN!

- Half day / part time position
- Assist in general marketing and branding operations
- Marketing degree / diploma essential
- Email CV to Renata@sahivcs.org

www.sahivsoc.org

Please don't forget to send me any info you may have on funding opportunities, meetings, workshops and/or conferences, so I can post it on the SAIS LinkedIn page. Additionally, if you are recruiting/hiring, I am more than happy to advertise it on LinkedIn and in the newsletter.

Kind regards

Dana Savulescu (PhD), Pr.Sci.Nat.

Mobile: +27 74 6800082

Email: danams79@gmail.com